1-5 of 5
James Hilger, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4307.
https://doi.org/10.1182/blood-2019-124213
Published: 2019
Journal Articles

Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma

Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Michael Wang, MD, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Javier Munoz, MD, Tycel J. Phillips, MD, Won-Seog Kim, MD PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Judith Trotman
Journal: Blood
Blood (2018) 132 (Supplement 1): 1592.
https://doi.org/10.1182/blood-2018-99-117224
Published: 2018
Journal Articles

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial

Yuqin Song, MD PhD, Keshu Zhou, MD, Dehui Zou, MD, Jianfeng Zhou, PhD, Jianda Hu, PhD, Haiyan Yang, PhD, Huilai Zhang, PhD, Jie Ji, MD, Wei Xu, MD PhD, Jie Jin, MD PhD, Fangfang Lv, MD, Ru Feng, MD, Sujun Gao, PhD, Daobin Zhou, MD, Haiyi Guo, MD, Aihua Wang, PhD, James Hilger, PhD, Jane Huang, MD, William Novotny, MD, Muhtar Osman, PhD, Jun Zhu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 148.
https://doi.org/10.1182/blood-2018-99-117956
Published: 2018
Journal Articles

Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

Pier Luigi Zinzani, MD PhD, Max S Topp, MD, Sam LS Yuen, MBBS, FRCPA, FRACP, Chiara Rusconi, MD, Isabelle Fleury, MD MSc, FRCPC, Barbara Pro, MD, Giuseppe Gritti, MD, Michael Crump, MD, Wanling Hsu, MS, Elizabeth A. Punnoose, PhD, James Hilger, PhD, Mehrdad Mobasher, MD, Wolfgang Hiddermann, MD
Journal: Blood
Blood (2016) 128 (22): 617.
https://doi.org/10.1182/blood.V128.22.617.617
Published: 2016
Journal Articles

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, MD, Guillaume Cartron, MD PhD, Michael Hallek, Barbara F. Eichhorst, MD, Mark Kozloff, MD, Thomas A. Giever, Gerard Lozanski, MD, Elizabeth A. Punnoose, PhD, Jue Wang, James Hilger, PhD, Mehrdad Mobasher, MD, Gilles Salles, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4393.
https://doi.org/10.1182/blood.V128.22.4393.4393
Published: 2016